Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ISB 2001

Next Previous
Drug Profile

ISB 2001

Alternative Names: ISB-2001; TREAT™ trispecific antibody - Ichnos Sciences

Latest Information Update: 11 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ichnos Sciences
  • Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins; Trispecific antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunologic cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Multiple myeloma
  • Preclinical Haematological malignancies

Most Recent Events

  • 02 Jun 2025 Ichnos Glenmark Innovation plans a registrational trial in Multiple myeloma
  • 02 Jun 2025 Efficacy, safety and pharmacokinetics data from a phase I trial in Multiple myeloma released by Ichnos Glenmark Innovation
  • 05 May 2025 ISB 2001 receives Fast Track designation for Multiple myeloma [Parenteral,Injection] (Second-line therapy or greater) in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top